TransThera Sciences Widens Loss in 2025

MT Newswires Live

03/31

TransThera Sciences (HKG:2617) widened its attributable loss in 2025 to 296 million yuan from 274.6 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.

The clinical-stage biopharmaceutical firm's loss per share stood at 0.76 yuan in the fiscal year, compared with 0.72 yuan in the previous corresponding year.

The firm did not record any revenue in both periods.

Other income and gains fell 49% to 9.2 million yuan from 17.9 million yuan in the year-ago period, mainly due to a decline in interest income from bank deposits and wealth management products and lower government grants.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2623435585"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2623435585\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2623435585?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623435585","market":"sg","top_or_hot":-1,"title":"TransThera Sciences Widens Loss in 2025","media":"MT Newswires Live","content":"<html><body><p> TransThera Sciences (HKG:2617) widened its attributable loss in 2025 to 296 million yuan from 274.6 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.</p><p>The clinical-stage biopharmaceutical firm's loss per share stood at 0.76 yuan in the fiscal year, compared with 0.72 yuan in the previous corresponding year.</p><p>The firm did not record any revenue in both periods.</p><p>Other income and gains fell 49% to 9.2 million yuan from 17.9 million yuan in the year-ago period, mainly due to a decline in interest income from bank deposits and wealth management products and lower government grants.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransThera Sciences Widens Loss in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransThera Sciences Widens Loss in 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-31 19:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> TransThera Sciences (HKG:2617) widened its attributable loss in 2025 to 296 million yuan from 274.6 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.</p><p>The clinical-stage biopharmaceutical firm's loss per share stood at 0.76 yuan in the fiscal year, compared with 0.72 yuan in the previous corresponding year.</p><p>The firm did not record any revenue in both periods.</p><p>Other income and gains fell 49% to 9.2 million yuan from 17.9 million yuan in the year-ago period, mainly due to a decline in interest income from bank deposits and wealth management products and lower government grants.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"药捷安康-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2623435585","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623435585","pubTimestamp":1774956404,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"TransThera Sciences  widened its attributable loss in 2025 to 296 million yuan from 274.6 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.The clinical-stage biopharmaceutical firm's loss per share stood at 0.76 yuan in the fiscal year, compared with 0.72 yuan in the previous corresponding year.The firm did not record any revenue in both periods.Other income and gains fell 49% to 9.2 million yuan from 17.9 million yuan in the year-ago period, mainly due to a decline in interest income from bank deposits and wealth management products and lower government grants.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02617":"药捷安康-B","BK1161":"生物科技"},"translate_title":"Tranthera Sciences 2025年亏损扩大","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1},"content_text":"TransThera Sciences (HKG:2617) widened its attributable loss in 2025 to 296 million yuan from 274.6 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.The clinical-stage biopharmaceutical firm's loss per share stood at 0.76 yuan in the fiscal year, compared with 0.72 yuan in the previous corresponding year.The firm did not record any revenue in both periods.Other income and gains fell 49% to 9.2 million yuan from 17.9 million yuan in the year-ago period, mainly due to a decline in interest income from bank deposits and wealth management products and lower government grants.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}